Highmark Commercial Medical Policy - Pennsylvania |
Medical Policy: | S-127-012 |
Topic: | Solitary Pancreas Transplantation |
Section: | Surgery |
Effective Date: | February 27, 2017 |
Issue Date: | July 23, 2018 |
Last Reviewed: | July 2018 |
|
This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.
Policy Position Coverage is subject to the specific terms of the member’s benefit plan. |
A solitary pancreas transplant may be considered medically necessary when the following criteria are met:
If patients has type 2 diabetes mellitus, must be insulin-dependent and have body mass index equal to or less than 32.
The following pancreas transplants are considered experimental/investigational and, therefore, not covered, due to the lack of evidence based literature:
Relative contraindications for pancreas transplantation include, but not limited to the following:
Documentation demonstrating medical necessity and a clear reason to circumvent these contraindications will be required with evaluation of this service.
Retransplantation
Pancreas retransplant (PRTx) after a failed primary pancreas transplant may be considered medically necessary provided the individual meets the transplant criteria above.
Also, a third or subsequent pancreas transplant is considered not medically necessary in all cases.
See Medical Policy Bulletin S-126 for information on simultaneous Pancreas/Kidney transplantation (SPK).
See Medical Policy Bulletin S-124 for information on Kidney Transplantation.
See Medical Policy Bulletin E-42 for information on artificial pancreas device systems.
Place of Service: Inpatient |
The policy position applies to all commercial lines of business |
Denial Statements |
Services that do not meet the criteria of this policy will not be considered medically necessary. A network provider cannot bill the member for the denied service unless: (a) the provider has given advance written notice, informing the member that the service may be deemed not medically necessary; (b) the member is provided with an estimate of the cost; and (c) the member agrees in writing to assume financial responsibility in advance of receiving the service. The signed agreement must be maintained in the provider’s records.
Services that do not meet the criteria of this policy will be considered experimental/investigational (E/I). A network provider can bill the member for the experimental/investigational service. The provider must give advance written notice informing the member that the service has been deemed E/I. The member must be provided with an estimate of the cost and the member must agree in writing to assume financial responsibility in advance of receiving the service. The signed agreement must be maintained in the provider’s records.
Links |